Hørsholm, Denmark June 17, 2016
Hoersholm, Denmark; June 17th, 2016 – Oncology Venture Sweden AB (OV:ST) announces that up to 6 million NOK (app. 632,000 EUR) has been granted by the Norwegian Research Council through the EUROSTARS program for the development of Oncology Venture’s immuno-oncology product APO010. The grant will i.a. cover the costs of a clinical proof of concept trial to investigate the effect of APO010 in patients with multiple myeloma (MM), a disease in the bone marrow. Patients entering the trial will be screened for high likelihood of effect of the drug by the use of Oncology Venture’s Drug Response Predictor (DRPTM) – a unique tool based on Big Data from a multi gene signature identified in the MM patients’ biopsies.